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The basic leucine zipper transcription factor CCAAT/enhancer binding protein alpha (CEBPA) codes for a
critical regulator during neutrophil differentiation. Aberrant expression or function of this protein
contributes to the development of acute myeloid leukemia (AML). In this study, we identified two novel
unrelated CEBPA target genes, the glycolytic enzyme hexokinase 3 (HK3) and the kru¨ppel-like factor 5
(KLF5) transcription factor, by comparing gene profiles in two cohorts of CEBPA wild-type and mutant
AML patients. In addition, we found CEBPA-dependent activation of HK3 and KLF5 transcription during
all-trans retinoic acid (ATRA) mediated neutrophil differentiation of acute promyelocytic leukemia (APL)
cells. Moreover, we observed direct regulation of HK3 by CEBPA, whereas our data suggest an indirect
regulation of KLF5 by this transcription factor. Altogether, our data provide an explanation for lowHK3 and
KLF5 expression in particular AML subtype and establish these genes as novel CEBPA targets during
neutrophil differentiation.
T
he CCAAT/enhancer binding protein alpha (CEBPA) is a master regulator of myeloid differentiation that
drives hematopoiesis towards the granulocytic lineage1. The relevance of CEBPA in the maintenance of
myeloid lineage is underlined by the fact that Cebpa-null mice lack the production of neutrophils and
eosinophils2. Not surprisingly, CEBPA functions are frequently disrupted in particular subtypes of acute myeloid
leukemias (AML), thereby contributing to the differentiation arrest seen in AML blast cells. Several groups
reported aberrant CEBPA function due to intragenetic mutations in 5–10% of AML patients (10–19% in normal
karyotype-AML) (Reviewed in3–6). Mutations in the CEBPA gene predominantly cause either a frame-shift at the
N-terminus resulting in the truncated CEBPA isoform p30 with dominant negative function, or disrupt the basic
zipper region at the C-terminus causing weakened DNA-binding (Reviewed in7,8). Furthermore, most AML
patients harbor CEBPA mutations on both alleles and these bi-allelic CEBPA mutated patients have a favorable
clinical outcome as compared to CEBPA-wild-type or patients with a mono-allelic mutation (Reviewed in5,6).
Lastly, transcriptional repression mediated by leukemic fusion proteins or epigenetic alterations such as aberrant
promoter hypermethylation further leads to low CEBPA expression in some AML patients9.
Our group recently reported a functional role for hexokinase 3 (HK3) and Kru¨ppel-like factor 5 (KLF5) in the
pathogenesis of AML10,11. HK3 (ATP:D-hexose 6-phosphotransferase) is a glycolytic enzyme most frequently
expressed in myeloid cells and represents the dominant hexokinase in granulocytes accounting for 70–80% of
total hexokinase activity10,12. We identifiedHK3 as a direct target of the transcription factors PU.1 and oncogenic
fusion protein PML-RARA in acute promyelocytic leukemia (APL) characterized by the t(15;17) translocation.
Inhibition of HK3 impairs neutrophil differentiation of APL cells and promotes cell death upon anthracycline
treatment. We found significantly reduced HK3 expression not only in APL but also in other AML subtypes
suggesting that additional mechanisms responsible for low HK3 levels in AML are operative10.
We and others found that members of the Kru¨ppel-like factor (KLF) family are often deregulated in primary AML
patient samples11. The KLF transcription factor family is composed of 17 members involved in diverse functions
such as proliferation, self-renewal, differentiation and apoptosis13. Among the different KLFs inhibited in AML,
KLF5 was found to be essential for granulocytic differentiation11,14. Low KLF5 expression in AML can partially be
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explained by hypermethylation of its promoter as shown in primary
AML and in several AML cell line models14. Still unclear is how KLF5
is transcriptionally regulated during granulocytic differentiation.
In this study we describe two novel CEBPA target genes, the gly-
colytic enzymeHK3 and the transcription factorKLF5, both of which
are significantly downregulated in CEBPA-mutated AML patients.
Results
Low HK3 and KLF5 expression is associated with CEBPA-mutated
AML. CEBPA is a master regulator of myeloid differentiation, whose
expression peaks in the granulocyte-monocyte progenitor cell stage,
and diminishes during terminal granulocyte differentiation3. Most
importantly, in different AML subtypes CEBPA expression or
function is inhibited by a variety of mechanisms3,5,6. In an attempt
to test whether HK3 and KLF5, two genes with a recently discovered
role in APL differentiation10,11,14, are novel CEBPA target genes, we
compared their expression in a total of 90 CEBPA-mutated or CEBPA
wild-type AML patients. HK3 and KLF5 were below the detection
limit in 11 and 16 AML patient samples, respectively. We compared
HK3 mRNA expression in CD341 samples (n 5 4) to 74 CEBPA-wt
and 5 CEBPA-mutated AML samples. KLF5 expression in 4 CD341
samples was compared to 70 CEBPA-wt and 4 CEBPA-mutated AML
samples. A detailed analysis of HK3 and KLF5 mRNA levels in
primary AML (FAB M0-M7) patient samples revealed a
significantly lower expression of HK3 and KLF5 in CEBPA-mutated
as compared to CEBPA wild-type AML samples (p , 0.01)
(Figure 1a–b). As seen for other CEBPA target genes identified by
screening AML patient cohorts, our results suggest that disrupting
CEBPA function impairs HK3 and KLF5 expression15. Next, we
confirmed that HK3 and KLF5 expression is significantly lower in
CEBPA-mutated, but not CEBPA wild-type patients from analysis
of a second AML patient cohort (n 5 154). Since these cohorts
contained patients with CEBPA single (SM) or double mutations
(DM), we could address whether single or double mutations alter
HK3 or KLF5 expression16. We found that HK3 or KLF5 expres-
sion was not significantly different from patient’s samples with
either CEBPA SM or DM (Figure 1c–d). Taken together, our find-
ings indicate that loss of HK3 or KLF5 expression correlated with
CEBPA mutations, irrespective of single or double CEBPA muta-
tions, whereas enhanced expression of HK3 or KLF5 correlated
with wild-type CEBPA expression.
CEBPA-dependent induction of HK3 and KLF5 during neutro-
phil differentiation of APL cells. To experimentally test whether
Figure 1 | HK3 and KLF5 expression is significantly downregulated in CEBPA-mutated AML patients. HK3 (a) and KLF5 (b) mRNA levels were
measured by qPCR in total RNA extracted from primary AML (FAB M0-M7) blasts, CD341 samples or granulocytes from healthy donors. Patient
characteristics are summarized in Supplementary Table 1.HK3 (c) and KLF5 (d) levels in 154 patients from the Taskesen cohort with normal karyotype,
expressing wild type CEBPA (WT), one allele mutated (SM) or two alleles mutated (DM).MWU: *p, 0.05, **p, 0.01, ***p, 0.001, ****p, 0.0001.
www.nature.com/scientificreports
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loss of CEBPAmRNA alters HK3 and KLF5 expression, we knocked
down CEBPA in the two APL cell line models NB4 and HT93. This
was accomplished using lentiviral vectors expressing two indepen-
dent short hairpin (sh)RNAs targeting theCEBPA gene. Knockdown
efficiency was evaluated by qPCR andWestern blotting (Figures 2a, e
and f). After 4 days of treatment with 1 mM ATRA to promote
neutrophil differentiation, we observed significantly reduced HK3
and KLF5 mRNA levels in the NB4 and HT93 CEBPA knock-
down cell lines as compared to the control cells (Figures 2b and c).
We evaluated G-CSFR expression in CEBPA knockdown cells
(Figure 2d) to validate inhibition of ATRA-induced neutro-
phil differentiation, while induction of CEBPE, a direct CEBPA
regulated gene17, was measured as an additional control
(Supplementary Figures S1a and b). Our results clearly demon-
strate that the upregulation of HK3 and KLF5 during neutrophil
differentiation of APL cells is CEBPA-dependent.
CEBPA binding to theHK3 or KLF5 promoters activates transcri-
ption.Our findings prompted us to investigate ifHK3 and KLF5 are
direct transcriptional targets of CEBPA. To this end, we first
analyzed the genomic regions surrounding exon 1 of these genes
for putative CEBPA binding sites using Matinspector 8.0. We
identified two putative CEBPA binding sites in both the HK3 and
the KLF5 genomic regions analyzed (Figure 3a and c). Chromatin
immunoprecipitation (ChIP) revealed binding of CEBPA at posi-
tions 1821/12963 and 2385/21576 relative to the transcriptional
Figure 2 | Genetic inhibition of CEBPA impairs HK3 and KLF5 upregulation during neutrophil differentiation of APL cells. (a) NB4 or HT93 APL cell
lines were stably transduced with pLKO.1 lentiviral vectors expressing non-targeting or two independent CEBPA-targeting shRNAs. APL control and
CEBPA knockdown cells were differentiated with 1 mMATRA for 4 days. Knockdown efficiency in NB4 (top panels) or HT93 (bottom panels) APL cells
was validated by qPCR. CEBPA mRNA expression was normalized to the housekeeping gene HMBS and is shown as n-fold changes compared to
untreated SHC002 control cells. HK3 (b) and KLF5 (c) mRNA expression in NB4 or HT93 APL cells was determined by qPCR and analyzed as in 2a.
Impairment in granulocytic differentiation of CEBPA knockdown cells was shown by a reduction of the neutrophil marker granulocyte colony-
stimulating factor receptor (GCSFR or CSF3R) (d) Data represent the mean6 s.d. of at least three independent experiments. (e), (f) CEBPAKnockdown
efficiency at the protein level inNB4 andHT93APL cells was confirmed bywestern blotting. GAPDH is shown as a loading control.MWU: *p, 0.05, **p
, 0.01 and ***p , 0.001.
www.nature.com/scientificreports
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start site on the HK3 and KLF5 genomic regions, respectively
(Figures 3b and d). We next asked whether CEBPA activates HK3
and KLF5 transcription from these sites using promoter reporter
assays. CEBPA co-expression with the different luciferase promoter
reporters resulted in a significant, dose-dependent activation of HK3
promoter A (up to 37-fold) and KLF5 (up to 11-fold) transcription,
respectively (Figures 3e and g). The HK3 promoter B containing the
CEBPA binding site 12963 was only induced 1.5-fold (Supplemen-
tary Figure S2a). To confirm the specific CEBPA-induction of the
promoter activity we mutated the CEBPA binding sites on the HK3
promoter A and the KLF5 promoter. Indeed, inactivating the CEBPA
binding site in the HK3 promoter significantly inhibited transcrip-
tional inhibition (Figure 3f). Surprisingly, however, introducing single
or double CEBPA binding sites mutations in the KLF5 promoter did
not attenuate transcriptional activity of the reporter construct
(Supplementary Figure S2b).
Ectopic expression of CEBPA significantly induces HK3 and
KLF5 transcription. To confirm CEBPA-dependent transcrip-
tional regulation of HK3 and KLF5, we overexpressed CEBPA in
HT93 APL cells by transiently transfecting a CEBPA expression
plasmid. Ectopic expression of CEBPA in HT93 cells resulted in a
significant 5.5- and 12.3-fold induction of HK3 and KLF5 gene
expression, respectively (Figures 4a and b). CEBPA transfection
efficiency was assessed by qPCR and Western blotting (Figure 4d
and e). In addition, induction of the direct CEBPA target CEBPEwas
measured as a positive control of CEBPA activity (Figure 4c). Next,
we used K562 leukemic cell lines expressing 4-OHT inducible full-
length CEBPA (CEBPA-p42-estrogen receptor (ER)), a truncated
isoform (CEBPA-p30-ER), or a p42 isoform with a mutation
preventing interaction with E2F and neutrophil differentiation
(CEBPA-BRM2-ER). After 24 h of 4-OHT treatment, we observed
a significant 2.5-fold transcriptional activation of KLF5 (p , 0.05)
upon CEBPA-p42-ER activation only, but not in ER control, nor in
CEBPA-p30-ER, or mutated CEBPA-BRM2-ER activated K562 cells
(Figure 4f), suggesting that induction ofKLF5 is a specific function of
the full length CEBPA p42 isoform. Interestingly, HK3 mRNA was
not detectable in K562 cells indicating that different HK isoforms
may be active in these cells. Induction of CEBPE was measured as a
positive control (Figure 4g). Altogether, our findings demonstrate
that CEBPA is a crucial positive regulator of HK3 and KLF5 during
granulocytic differentiation.
Figure 3 | CEBPA binds to and activates the HK3 and the KLF5 promoters. Schematic representation of a 6 kb humanHK3 (a) and a 5 kb humanKLF5
(c) genomic regions retrieved from an online database. MatInspector software predicted two putative CEBPA binding sites (squares) in the DNA
sequences analyzed. In vivo binding of CEBPA to these CEBPA consensus sites in the HK3 (b) or KLF5 (d) genomic regions was shown by chromatin
immunoprecipitation (ChIP) in NB4 APL cells. As a negative control for the different pull downs, absence ofGAPDH amplification is shown. *unspecific
band, primer dimer. Two HK3 (e–f) and one KLF5 genomic region (g) containing the CEBPA binding sites were PCR amplified from genomic DNA of
NB4 cells using proof reading PfuDNApolymerase and cloned into the pGL4.10-basic vector. H1299 cells were transiently transfectedwith 40 ng of either
HK3 promoter reporter construct A (e), construct A with mutated CEBPA binding site (f, wild-type GAAAGAC, mutated GGTCGAC) or the KLF5
promoter reporter construct (g), together with pcDNA3.1 empty vector or increasing concentrations (40–80–120 ng) (e,g) or 80 ng of CEBPA expression
vector (f). The promoter activity is shown as relative light units (RLU) relative to pcDNA3.1 control transfected cells. Results are the means 6 s.d. of at
least triplicate transfections. MWU: **p , 0.01, ***p , 0.001.
www.nature.com/scientificreports
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Discussion
Reduced CEBPA expression or loss of function mutations are com-
monly observed in AML suggesting that the deregulation of CEBPA
function is amajor event in the development of AML18–20. Identifying
new CEBPA target genes and associated CEBPA-dependent path-
ways in myeloid differentiation may provide novel insights into the
differentiation block as well as into ancillary cellular functions found
in AML. Interestingly, CEBPA has been described as a pivotal regu-
lator of various metabolic processes in different cell types21.
Nevertheless, whether CEBPA regulates metabolic activity in mye-
loid cells is of yet unclear. Our findings now link CEBPA to glycolysis
via direct positive regulation of the glycolytic enzymeHK3. We have
previously shown that HK3 expression is repressed in AML, particu-
larly in APL, where low HK3 levels are the result of PML-RARA
repression and low expression of its positive regulator PU.110. Our
results demonstrate that CEBPA is an additional critical regulator of
HK3 expression in AML and during neutrophil differentiation of
APL cells. Furthermore, our findings show that the lowest HK3
expression is found in CEBPAmutated patients and may contribute
to the differentiation block in this AML subtype.
In general, AML is defined by a block in differentiation and an
increased proliferation of immature myeloid progenitors18.
Additionally, loss of CEBPA-mediated cell-cycle arrest is crucial
for the development of AML15,22,23. Since KLF5 regulates genes
involved in cell cycle regulation and apoptosis, it may represent a
relevant downstream effector of CEBPA-induced cell cycle arrest
(reviewed in24). In the myeloid lineage, KLF5 induces differentiation
and functions as a tumor suppressor and its low expression inAML is
partially explained by epigenetic silencing11,14,25. Importantly, low
KLF5 expression is associated with poor overall survival26. In this
study, we suggest an additional mechanism for low KLF5 levels in
AML that is loss of positive regulation of KLF5 due to impaired
CEBPA function. Since mutating the CEBPA binding sites in the
KLF5 promoter constructs did not change the responsiveness of
these reporters to CEBPA expression, CEBPAmay indirectly activate
KLF5 transcription. The KLF5 promoter lacks a TATA box, but
contains a GC-rich region that is activated by the transcription factor
Sp127. Moreover, CEBPA can functionally interact with Sp1, e.g. in
regulating the CD11c integrin gene28. We propose, that CEBPA
induces KLF5 transcription, similarly to CD11c regulation, via Sp1.
Figure 4 | Ectopic expression of CEBPA activates HK3 and KLF5 transcription. (a–e) HT93 cells were transiently transfected with pcDNA3.1 empty
control or a CEBPA expression vector.HK3 (a) andKLF5 (b) mRNA expression was quantified by qPCR. Data were normalized to HMBS and are shown
as n-fold regulation as compared to control transfected cells. Induction of CEBPE mRNA, a direct target gene of CEBPA, was measured as a positive
control for CEBPA activity (c). Results are the means 6 s.d. of at least triplicate transfections. CEBPA transfection efficiency was measured by qPCR (d)
andwestern blotting (e). GAPDH is shown as a loading control. (f–g)Different CEBPA-ER fusion constructs were induced by treating the respective K562
cell lines with 5 mMTamoxifen for 24 h.HK3 (f) orKLF5 (g) mRNA expression was quantified by qPCR as in 2a. Expression of the CEBPA targetCEBPE
was measured as positive control for CEBPA activation in wildtype CEBPA p42 expressing K562 cells. MWU: *p , 0.05, **p , 0.01.
www.nature.com/scientificreports
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In conclusion, we identified HK3 and KLF5 as novel CEBPA-
regulated genes in AML and during APL differentiation underlining
their tumor suppressor function in AML as well as their role in
granulopoiesis.
Methods
Patient samples, cell lines and cell culture conditions. Fresh leukemic blast cells
from untreated AML patients at diagnosis obtained at the Inselspital Bern
(Switzerland) were classified according to the French-American-British (FAB)
classification and cytogenetic analysis. All leukemic samples displayed a blast count of
.90% after separation of mononuclear cells using a Ficoll gradient (LymphoprepTM,
Axon Lab AG, Switzerland) as described previously10,11. PBMC and granulocytes
obtained from normal, healthy donors were isolated using a Ficoll gradient.
The human acute promyelocytic leukemia (APL) cell lines NB4 and HT93 were
maintained in RPMI-1640 (Sigma-Aldrich) with 10% fetal calf serum (FCS,
Biochrom, AG), 50 U/mL penicillin and 50 mg/mL streptomycin (Sigma-Aldrich) in
a 5% CO2-95% air humidified atmosphere at 37uC.
For differentiation experiments, NB4 cells were seeded at a density of 0.2 3 106/ml
and treated with 1 mM all-trans retinoic acid (ATRA, dissolved in DMSO, Sigma
Aldrich) as indicated. Successful neutrophil differentiation was assessed by light
microscopy using May-Gru¨nwald-Giemsa (Merck, Darmstadt, Germany) stained
cells and by surface expression of the differentiation marker CD11b (Immunotools).
Briefly, 5 3 105 cells were collected, washed, and incubated with monoclonal mouse
phycoerythrin (PE)-labeled anti-human-CD11b for 20 min at 4uC. Fluorescence
intensity was then measured by a FACS Calibur flow cytometer (Becton Dickinson,
Basel, Switzerland) and analyzed using FlowJo Software.
K562-CEBPA-p42-ER, K562-CEBPA-p30-ER, K562-CEBPA-BRM2-ER and
K562-ERwere kindly provided by Prof. G. Behre and weremaintained in RPMI-1640
supplied with 10% fetal calf serum (FCS), 50 U/mL penicillin and 50 mg/mL strep-
tomycin in a 5% CO2-95% air humidified atmosphere at 37uC. K562 CEBPA-ER cells
were differentiated as described15 by addition of 5 mM 4-OHT (Sigma-Aldrich).
Chromatin immunoprecipitation (ChIP). ChIP was performed using the ChIP-IT
Express Chromatin Immunoprecipitation Kit (ChIP-IT Express, Active Motif,
Rixensart, Belgium) according to the manufacturer’s recommendations. For
immunoprecipitation, an anti-CEBPA antibody (sc-61X Santa Cruz, CA, US) was
used. Antibodies against acetyl-histone H3 (Stratagene, La Jolla, CA, US) and IgG
(PP64B, Upstate, Millipore) served as positive and negative controls, respectively.
PCR was performed using the following primers: HK3 promoter A, F:
GGGCTACTTGGGGATTGCTTCACA, R: ACGTGTCTTTCTCAAGGCCCAGC;
HK3 promoter B, F: TCAGCCTTTCCAGTGCTCTCTCA, R: CTGTAGCAGTC-
AACCAGAAGGCCC; KLF5 promoter A, F: 59-ACAGCATGGGGCTGCTTGGT -
39, R: 59-TGCCTTCAGAGAATGGCTGATGAC -39; KLF5 promoter B, F: 59-
GCGCCCCTACCTAGCTGCCT-39, R: 59-GGTGGAGACGCGGAGGGAGA-39.
As a negative control for the different pulldowns, absence ofGAPDH amplification is
shown29.
Human HK3 and KLF5 promoter reporter assays and mutagenesis. Two HK3
promoter regions and oneKLF5 promoter region containing the CEBPAbinding sites
were PCR amplified from genomic DNA of NB4 APL cells using proof reading Pfu
DNA polymerase (Promega, Du¨bendorf, Switzerland) and cloned into the pGL4.10-
basic vector (Promega). All mutants were introduced using the QuickChange site-
directed mutagenesis system (Agilent, CA, USA) according to the manufacturer’s
instructions. Promoter transactivation assays were performed as previously
described10. Briefly, H1299 cells were transiently transfected with 40 ng of the
promoter reporter constructs together with pcDNA3.1 empty or CEBPA expression
vector. The promoter activity was measured using the Dual-Luciferase Reporter
Plasmid System (Promega) and is shown as relative light units (RLU) relative to
pcDNA3.1 control transfected cells.
TaqMan Low Density Array (LDA) and real-time quantitative reverse
transcription PCR (qPCR). RNA extraction, RT-PCR and LDA measurements, as
well as data analysis were done as described10,11. Total RNA was extracted using the
RNeasy Mini Kit and the RNase-Free DNase Set according to the manufacturer’s
protocol (Qiagen, Hombrechtikon, Switzerland). Total RNA was reverse transcribed
using random primers (Roche Diagnostics) and M-MLV reverse transcriptase
(Promega). PCR and fluorescence detection were performed using the ABI PRISMH
7500 Sequence Detection System (Applied Biosystems, Rotkreuz, Switzerland). Data
represent log2 expression levels and the measured cycle threshold (Ct) values were
normalized to the expression levels of the housekeeping genes HMBS and ABL1.For
quantification of KLF5, CEBPA, CEBPE and G-CSFRmRNA in human cells we used
TaqmanH Gene Expression Assays Hs00156145_m1, Hs00269972_s1,
Hs00357657_m1, and Hs00167918_m1, (Applied Biosystems), respectively. HMBS
as well as ABL-1 primers and probes have been previously described10,11.
Cell lysate preparation and Western blotting. Whole cell extracts were prepared
using RIPA lysis buffer supplemented with 8 M UREA according to the protocol
found at www.abcam.com. 40–60 mg total protein was loaded on a 10% or 12%
denaturing polyacrylamide gel. Blots were incubated with the primary antibodies in
TBS 0.05%Tween-20/5%milk overnight at 4uC, incubated with secondary antimouse
or -rabbit antibody at 155–10,000 for 1 h at room temperature, and analyzed using
the Odyssey infrared imaging system detection (Li-Cor Biosciences). Primary
antibodies used were anti-CEBPA (Abcam) 15500 and anti-GAPDH (Millipore)
1559000. Secondary antibodies used were goat anti-rabbit IRDye H 800CW and goat
anti-mouse IR Dye H 680LT (Li-Cor Biosciences).
Transient transfection. HT93 cells were transiently transfected using a cell
nucleofector kit (Amaxa Biosystems) according to the manufacturer’s instructions.
Briefly, the cells were washed in PBS and then resuspended in nucleofector solution to
a final concentration of 2 3 106 cells per 100 ml each. Afterwards, the cell suspension
was mixed with plasmid DNA pcDNA3.1 either empty, as a negative control, or
expressing CEBPA, using the program X-01 and incubated at 37uC and 5% CO2 for
24 h.
Lentivirus preparation and transduction of target cells. pLKO.1-puro lentiviral
vectors expressing shRNAs targeting CEBPA (shCEBPA_1: NM_004364.2-171s1c1
or shCEBPA_2: NM_004364.2-1335s1c1) or the control vector (SHC002) were
purchased from Sigma-Aldrich. All vectors contain a puromycin antibiotic resistance
gene for selection of transduced mammalian cells. Lentivirus production and
transduction were done as described10,11. Transduced HT93 and NB4 cells were
selected with 1.5 mg/ml puromycin for 4 days and knockdown efficiency was
validated by qPCR.
Statistical analysis.Nonparametric Mann-Whitney-U (MWU) tests were applied to
compare the difference between two groups usingGraphPad Prism 4 software (Graph
Pad Software, San Diego, CA). P-values , 0.05 were considered statistically
significant. HK3 and KLF5 promoter regions were retrieved from an online database
(www.ncbi.nlm.nih.gov), while the putative CEBPA binding sites were predicted by
MatInspector (www.genomatix.de).
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